BioGend Therapeutics Co., Ltd. (TPEX:6733)
Taiwan · Delayed Price · Currency is TWD 36.80
+0.30 (0.82%)
Feb 11, 2026, 1:30 PM CST
BioGend Therapeutics Revenue
BioGend Therapeutics had revenue of 61.66M TWD in the quarter ending September 30, 2025, with 39.34% growth. This brings the company's revenue in the last twelve months to 212.43M, up 35.61% year-over-year. In the year 2024, BioGend Therapeutics had annual revenue of 167.65M with 52.53% growth.
Revenue (ttm)
212.43M
Revenue Growth
+35.61%
P/S Ratio
21.37
Revenue / Employee
n/a
Employees
n/a
Market Cap
4.54B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 167.65M | 57.74M | 52.53% |
| Dec 31, 2023 | 109.91M | 78.46M | 249.51% |
| Dec 31, 2022 | 31.45M | 22.18M | 239.26% |
| Dec 31, 2021 | 9.27M | 7.88M | 565.40% |
| Dec 31, 2020 | 1.39M | -68.00K | -4.65% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Panion & Bf Biotech | 2.04B |
| Medigen Biotechnology | 1.59B |
| ACRO Biomedical | 36.50M |
| UnicoCell Biomed | 34.58M |
| AnnJi Pharmaceutical | 23.85M |
| Formosa Pharmaceuticals | 12.16M |
| Energenesis Biomedical CO.,LTD. | 7.46M |
| Locus Cell | 5.18M |